Tuesday, April 27, 2021

COVID Research Supports The Institute’s Core Mission to Save Lives and Empower Healthcare Equity

LOS ANGELES, CA — April 27, 2021 — Investigators at The Lundquist Institute at Harbor-UCLA Medical Center, a leading clinical research center on life-saving vaccines and treatments, have been among the first and foremost to respond against COVID-19. Since March 2020, The Lundquist Institute has led or participated in eight COVID-19 clinical studies and the results of this research have changed the world. This timely and vigorous response was due to the number of early cases and extreme COVID-19 infection surges in south-central Los Angeles.

Saturday, April 17, 2021

Matthew Budoff, MD, Will Present the Analyses at the European Society of Cardiology (ESC) Preventive Cardiology 2021

Investigator(s): Matthew Budoff, MD

LOS ANGELES (April 17, 2021) — Today, The Lundquist Institute announced that Matthew Budoff, MD, Director of Cardiovascular CT at the Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, will present further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial as Late- Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology.

Tuesday, April 13, 2021

For Critically Ill Patients with Advanced Medical Illnesses and Poor Prognoses, Overuse of Invasive ICU Treatment May Prolong Suffering

Investigator(s): Dong Chang, MD

LOS ANGELES (April 13, 2021) — The Lundquist Institute (TLI) Investigator Dong W. Chang, MD, and his colleagues’ study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study – “Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments” – found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings.

Monday, March 8, 2021

Bill & Melinda Gates Medical Research Institute To Develop Formulation

-Agreement advances evolution of synthetic lung surfactants to treat respiratory distress Syndrome in premature infants in Low- and Middle-Income Countries-

Investigator(s): Frans Walther, MD, PhD, FAAP

LOS ANGELES — The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe.
 

Wednesday, March 3, 2021

The Lundquist Institute researchers discovered a natural compound that exhibits almost ideal male contraceptive effects in pre-clinical studies

Investigator(s): Wei Yan, MD, PhD

LOS ANGELES — In a new paper published by Nature Communications, The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues spell out an innovative strategy that has led to the discovery of a natural compound as a safe, effective and reversible male contraceptive agent in pre-clinical animal models. Despite tremendous efforts over the past decades, the progress in developing non-hormonal male contraceptives has been very limited.  

Wednesday, February 10, 2021

The grant will fund clinical trials to study the efficacy of psilocybin in treating the emotional suffering associated with terminal medical illness

Investigator(s): Charles Grob, MD

LOS ANGELES — The Lundquist Institute has received a $1.75 million grant from the Steven & Alexandra Cohen Foundation to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The grant will also support education and outreach programs related to the use of psilocybin within the field of palliative care.

Wednesday, February 3, 2021

Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits

THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.

Tuesday, January 19, 2021

Ashraf S. Ibrahim, PhD, Lead Author, on publication in the world’s No. 1 Scientific Journal for Microbiology

Investigator(s): Ashraf Ibrahim, PhD

LOS ANGELES — Today Nature Microbiology publishes The Lundquist Institute Investigator Dr. Ashraf Ibrahim and his co-authors’ paper, “Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis.”

Tuesday, December 15, 2020

In a Year Dominated by the Global COVID Pandemic, The Institute Kept Moving Forward

 

LOS ANGELES — The Lundquist Institute, a world leader in biomedical research, today released its 2020 Year in Review video. 2020 was an unparalleled year and given the challenge of working against the backdrop of the global COVID pandemic, the Institute had one of its most outstanding years ever.

Thursday, November 19, 2020

California Institute for Regenerative Medicine (CIRM) Funds New Research on Nanotechnology for Stem Cell Implantation and Diabetes Treatment

LOS ANGELES — Two junior Investigators at the The Lundquist Institute, Dr. Eiji Yoshihara and Dr. Lina R. Nih, have received a Quest Award from the California Institute for Regenerative Medicine (CIRM). The Quest Award is for discovery research and aims to promote promising new technologies that could be translated for broad use and improved patient care.